Novartis partner Ophthotech says wet-AMD drug Fovista goes 0-for-3 in PhIII
Ophthotech’s lead drug is now a three-time loser in Phase III.
The biotech $OPHT had already largely written off the anti-PDGF Fovista after it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
